Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. FEED
FEED logo

FEED Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.920
Open
1.890
VWAP
1.88
Vol
61.71K
Mkt Cap
2.05M
Low
1.830
Amount
115.81K
EV/EBITDA(TTM)
--
Total Shares
1.09M
EV
-1.86M
EV/OCF(TTM)
--
P/S(TTM)
0.18
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
Show More

Events Timeline

(ET)
2026-02-24
08:40:00
ENvue Medical Receives Patent Approval for Feeding Tube
select
2026-01-28 (ET)
2026-01-28
09:10:00
ENvue Medical Signs Distribution Agreement with U-Deliver
select
2026-01-21 (ET)
2026-01-21
08:40:00
ENvue Medical Appoints Marc Waldman as Vice President, Commercial
select
2026-01-14 (ET)
2026-01-14
08:40:00
ENvue Medical Launches OTC ENFit Syringes
select
2026-01-09 (ET)
2026-01-09
09:10:00
ENvue Medical Launches New Program to Improve Comfort of Nasogastric Tube Use
select
2025-12-18 (ET)
2025-12-18
09:10:00
ENvue Medical's UroShield Kit Added to UK NHS Drug Tariff
select

News

Benzinga
9.5
01-29Benzinga
Meta Platforms Reports Strong Q4 Earnings, Shares Surge
  • Strong Financial Results: Meta reported fourth-quarter revenue of $59.89 billion, exceeding analyst expectations of $58.30 billion, indicating robust performance in the recovering advertising market, which is likely to drive further stock price increases.
  • Earnings Growth: The company posted adjusted earnings of $8.88 per share, surpassing the forecast of $8.16 per share, reflecting significant improvements in cost control and operational efficiency, thereby boosting investor confidence.
  • Stock Price Surge: Following the earnings report, Meta's shares jumped 8.2% in pre-market trading to $723.70, indicating a positive market sentiment towards the company's growth prospects, which may attract more investor interest.
  • Optimistic Sales Guidance: Meta's first-quarter sales guidance exceeded market expectations, further solidifying its leadership position in the digital advertising space and suggesting continued benefits from the recovery in advertising spending.
stocktwits
7.5
01-28stocktwits
ENvue Partners with U-Deliver for Nationwide Syringe Distribution
  • Stock Surge: ENvue Medical, Inc. (FEED) shares soared 138% on Wednesday following the announcement of a distribution agreement with U-Deliver, indicating strong market enthusiasm for its new product line.
  • Product Launch: The recently launched ENFit syringe line is designed to meet clinical needs for both feeding and medication delivery without requiring a prescription, enhancing its competitive edge in the market.
  • Distribution Channel Expansion: The new agreement will leverage U-Deliver's digital and wholesale channels to broaden access to the ENFit syringes, which is expected to significantly increase market penetration.
  • Market Sentiment Shift: On Stocktwits, retail sentiment around FEED shifted from 'bearish' to 'extremely bullish', with message volume rising from 'low' to 'extremely high', reflecting investor optimism about the company's future prospects.
NASDAQ.COM
7.5
01-28NASDAQ.COM
ENvue Medical Partners with U-Deliver to Expand ENFit Syringe Distribution
  • Market Expansion Partnership: ENvue Medical has signed a new distribution agreement with U-Deliver, leveraging its digital and wholesale channels to broaden access to ENFit syringes nationwide, thereby enhancing the company's competitive position in the non-acute enteral care market.
  • Product Innovation: The ENFit syringes meet ISO 80369-3 global standards and are available in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, supporting safe feeding and medication delivery for patients and caregivers.
  • Reusable Advantage: These syringes can be reused for up to seven days or 20 uses without a prescription, aimed at supporting continuity of care in home and long-term care settings, thereby improving patient quality of life.
  • Stock Performance: Following a 1-for-10 reverse stock split on December 8, 2025, ENvue Medical's stock is currently trading at $2.47, reflecting a 135.67% increase, indicating positive market sentiment towards the new partnership.
Benzinga
7.5
01-28Benzinga
ENvue Medical Partners with U-Deliver for Nationwide Distribution of ENFit Syringes
  • Distribution Agreement: ENvue Medical has signed a distribution agreement with U-Deliver to distribute its newly launched ENFit syringe product line nationwide through non-acute care channels, aiming to enhance market coverage and meet clinical needs.
  • Product Features: The ENFit syringes are designed for reuse, catering to both feeding and medication delivery clinical needs, supporting safe and reliable use in clinical and home care environments with a lifespan of up to seven days or 20 uses.
  • Market Performance: ENvue Medical shares rose 20.124% to $1.26 during premarket trading on Wednesday, reflecting positive market response to its new product line, despite the current stock price being close to the 52-week low of $0.99.
  • Strategic Rebranding: The company has rebranded to ENvue Medical, which better reflects its new strategic focus on intelligent, non-invasive solutions for enteral care, aiming to strengthen its competitive position in the non-acute enteral care market.
Benzinga
9.5
01-28Benzinga
F5, Inc. Reports Strong Q1 Results and Raises FY26 Guidance
  • Earnings Beat: F5, Inc. reported Q1 earnings of $4.45 per share, exceeding analyst expectations of $3.65 by 21.88%, indicating a significant improvement in profitability that is likely to positively impact stock prices.
  • Revenue Growth: The quarterly revenue reached $822.47 million, surpassing the Street estimate of $758.08 million, demonstrating enhanced competitiveness in the market that may attract more investor interest.
  • Optimistic Outlook: The company provided second-quarter sales guidance above estimates and raised its FY26 guidance, reflecting management's confidence in future growth, which could further drive stock price increases.
  • Positive Stock Reaction: F5 shares jumped 10.9% to $299.99 in pre-market trading, indicating strong market response to its earnings report, which may draw in more investors and bolster market confidence.
Globenewswire
5.0
01-21Globenewswire
ENvue Medical Appoints Marc Waldman as VP of Commercial to Drive Revenue Growth
  • Leadership Change: ENvue Medical has appointed Marc Waldman as Vice President of Commercial, where he will lead the company's U.S. commercialization strategy across 38 hospitals, aiming to accelerate revenue growth and expand market presence.
  • Extensive Industry Experience: Waldman brings over 35 years of experience in the medical device industry, having previously worked at NeoMed and Avanos Medical, where he successfully increased North American sales from approximately $39 million to $70 million, showcasing his exceptional sales leadership.
  • Strategic Execution: During his tenure at Avanos, Waldman guided the organization through a significant transition from a dealer-only model to a hybrid structure, leveraging both direct and dealer partnerships to enhance market competitiveness and optimize the business model.
  • Industry Influence: As Chairperson of the Global Enteral Device Supplier Association, Waldman plays a crucial role in advancing enteral safety standards, further enhancing ENvue's influence and reputation within the healthcare industry.

Valuation Metrics

The current forward P/E ratio for ENvue Medical Inc (FEED.O) is -0.00, compared to its 5-year average forward P/E of -0.00. For a more detailed relative valuation and DCF analysis to assess ENvue Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.00
Current PE
-0.00
Overvalued PE
-0.00
Undervalued PE
-0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.87
Current PS
0.55
Overvalued PS
1.04
Undervalued PS
0.71

Financials

AI Analysis
Annual
Quarterly

Whales Holding FEED

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is ENvue Medical Inc (FEED) stock price today?

The current price of FEED is 1.88 USD — it has decreased -2.59

What is ENvue Medical Inc (FEED)'s business?

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.

What is the price predicton of FEED Stock?

Wall Street analysts forecast FEED stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEED is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ENvue Medical Inc (FEED)'s revenue for the last quarter?

ENvue Medical Inc revenue for the last quarter amounts to 722.00K USD, increased 92.02

What is ENvue Medical Inc (FEED)'s earnings per share (EPS) for the last quarter?

ENvue Medical Inc. EPS for the last quarter amounts to -0.91 USD, decreased -97.68

How many employees does ENvue Medical Inc (FEED). have?

ENvue Medical Inc (FEED) has 15 emplpoyees as of March 11 2026.

What is ENvue Medical Inc (FEED) market cap?

Today FEED has the market capitalization of 2.05M USD.